US Stem Cell, Inc., a biotechnology company, is focused on the discovery, development and commercialization of autologous cell therapies for the treatment of acute and chronic heart damage, vascular and autoimmune diseases in the United States and internationally. Its leading product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body to improve heart function in patients with chronic heart failure; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic cardiac ischemia, and lower limb ischemia. The company’s product development line includes MyoCell SDF-1, an autologous muscle-derived cell therapy to improve cardiac function in patients with chronic heart failure. It is also developing MyoCath, a deflecting-tip needle injection catheter used to inject cells into heart tissue in therapeutic procedures to treat chronic cardiac ischemia and congestive heart failure. In addition, the company offers clinician- and patient-based cell therapy/regenerative medicine/cell therapy training, cell harvesting, and cell storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. a deflection needle injection catheter used to inject cells into heart tissue in therapeutic procedures to treat chronic cardiac ischemia and congestive heart failure. In addition, the company offers clinician- and patient-based cell therapy/regenerative medicine/cell therapy training, cell harvesting, and cell storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. a deflection needle injection catheter used to inject cells into heart tissue in therapeutic procedures to treat chronic cardiac ischemia and congestive heart failure. In addition, the company offers clinician- and patient-based cell therapy/regenerative medicine/cell therapy training, cell harvesting, and cell storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. cell collection and storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. cell collection and storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. cell collection and storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. cell collection and storage services; and cell collection and treatment kits for humans and animals, and also operates a cell therapy clinic. The company was previously known as Bioheart, Inc. and changed its name to US Stem Cell, Inc. in October 2015. US Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
You can now buy shares of US Stem Cell (USRM) | Step by Step
Are you interested in buying US Stem Cell (USRM) shares on OTC easily and using a regulated and reliable broker? Would you like to be able to invest your profits from the piggy bank and get a return on the stock market? Here I am going to show you how you can invest in DeGiro , a reliable Dutch investment broker with minimal commissions, and how you can get your first shares of US Stem Cell, Inc. (USRM) (USRM) quickly and intuitively.
The method is easy to carry out :
- To start we will register in Degiro, a broker platform in which we will invest in the shares of US Stem Cell, Inc. (USRM), (USRM).
- In the second step we will enter money to carry out our 1st investment.
- When we see the funds, what we are going to do is search for the US Stem Cell company using its Ticker, USRM.
- To finish we must indicate the number of shares we want, the purchase price and type of order.
Perhaps this checklist has been a bit essential for you, so I am going to show you step by step with images:
How to start investing in DeGiro.
The first step is to register in degiro through this link :
It will ask us for an email, a username and a password to enter, and then we will continue from the link that they have sent us by e-mail.
Soon degiro will require some important data in order to validate our identity . We must have at hand the passport, ID or driving license, our mobile number and the number of the bank account that we will use to make our first deposit. If you don’t understand how this format is, you can check this simple tutorial that we elaborated from Educaceps.es .
Once our account is confirmed we will have to enter money from the Enter / Withdraw tab. We can carry out a transaction that will take between 2-3 days, or make the deposit instantly thanks to Sofort, a 100% secure and 100% reliable payment gateway.
How to buy US Stem Cell (USRM) shares via degiro
As soon as we have the money we will be able to buy our 1st share. You can use the Place Order button at the top right or explore in the DeGiro search engine and put the ticker. In the next image you will see that I have written the Amazon Ticker but in your case you should put (USRM), the US Stem Cell ticker. As we are talking about an action, we will perceive that the related results are listed and there we will look to find US Stem Cell. The essential thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case US Stem Cell, Inc. (USRM) is listed on OTC. This step is very important so make no mistake.
At the time of placing the order we must pay attention to what I am going to explain to you . We can place a limit or market order. Think you want to get a US Stem Cell stock at 0.0279, but its price today is quite high. With a limit order we will place the value at which we plan to carry out the operation and until there are no shares for sale at a certain value, the purchase of the share will not be executed. With a market order, DeGiro will buy the number of shares that we have adjusted to today’s selling price, which will be very similar to the current trading price.
In both cases it is essential that you look at the type of organization: permanent or daily . As an example, in Spain, the stock market price is from tomorrow until 1 in the afternoon, and in the USA it coincides with the Spanish afternoon schedule. If the order is permanent, it will be kept until it is executed, but if you prefer the “of the day” option, at the time the session ends, if it is not executed, it will be removed from your Activity history – Pending Orders.
I hope this quick article helped you to invest in US Stem Cell.
| Company information |
|
company executives
| Name | Title | Payment | exercised | Year of birth |
|---|---|---|---|---|
| Mr Michael Tomas | CEO, Pres, CFO and Director | 1.81 million | N/A | 1966 |
| Dr Colleen Robb | Senior Compliance Officer | N/A | N/A | N/A |
| Mr Phil Posa | Senior Vice President of US and International Sales | N/A | N/A | N/A |
| Mrs. Evelyn Flores | Controller Corp. | N/A | N/A | N/A |
| Dr. Sergio Pinski | Medical director and member of the scientific advisory board | N/A | N/A | N/A |
| Mr. James L. Greene | Clinical Operations Consultant | N/A | N/A | N/A |
| Fabianne Gerson | Consultant | N/A | N/A | N/A |
Recent US Stem Cell Events:
Recent Events May 15, 2020 Filed Full 8-K: Other Events March 31, 2020 Filed Full 8-K: Other Events November 6, 2019 Filed Full 10-Q: Quarterly Report Oct 24, 2019 Filed Full 8-K : Completion of Acquisition or Disposition of Assets, Financial Statements, and Oct 15, 2019 Filed Full 8-K: Notice of Delisting or Failure to Follow a Standard or Continuing Listing Rule